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A B S T R A C T
Background and aims: This clinical trial was carried out to assess the eﬀects of probiotic on mental and motor
behaviors, metabolic proﬁles in patients with multiple sclerosis (MS).
Methods: Forty-eight patients with MS were treated by probiotics or placebo for four months to determine
clinical symptoms, mental health, and metabolic proﬁles.
Results: Probiotic decreased expanded disability status scale (−0.52 ± 0.04 vs.+ 0.16 ± 0.07, P < 0.001),
beck depression inventory (−5.08 ± 0.71 vs. −2.62 ± 0.78, P= 0.026), general health questionnaire-28
(−6.7 ± 1.17 vs. −3.04 ± 1.13, P= 0.03) and depression anxiety and stress scale (−12.54 ± 1.81 vs.
−3.33 ± 2.26, P= 0.003). Probiotic reduced malondialdehyde (P < 0.001) and 8-hydroxy-2′-deoxyguanosine
(P < 0.001). Probiotic resulted in a signiﬁcant reduction in IL-6 (P= 0.01) and high-sensitivity C-reactive
protein (P=0.03), and a signiﬁcant increase in IL-10 (P < 0.001) and nitric oxide levels (P= 0.012).
Conclusion: Through modulation of intestinal ﬂora, the probiotic bacteria may improve clinical symptoms by
balancing the inﬂammatory and anti-inﬂammatory responses, and adjusting the oxidative biomarkers in the MS
patients.
Clinical registration: http://www.irct.ir: IRCT2017082234497N2.
1. Introduction
Multiple sclerosis is an autoimmune and inﬂammatory demyeli-
nating disease related to central nervous system (CNS) that is char-
acterized by spinal cord syndrome, brainstem or cerebellar syndrome
cognitive impairment and optic neuritis (Sand, 2015). The disease af-
fects 2,500,000 people worldwide (Browne et al., 2014). The patho-
physiology of MS is multifactorial. It is documented that inﬂammatory
factors (Kouchaki et al., 2017), oxidative stress pathways (Morel, Bijak,
Niwald, Miller, & Saluk, 2017) and insulin resistance (Oliveira et al.,
2014) play a pivotal role in pathophysiology of MS; all correlated with
increasing expanded disability status scale (EDSS) which is known as a
main criteria for severity of MS (Kouchaki et al., 2017; Morel et al.,
2017; Oliveira et al., 2014). Also, the prevalence of anxiety and de-
pression is high in patients with MS (Boeschoten et al., 2016).
The gut microbiota consists of a population of bacteria that inhabits
the gut accounting for 70% of microbes in the human body (Bäckhed,
Ley, Sonnenburg, Peterson, & Gordon, 2005). Gut microorganisms live
in symbiosis with the host and aﬀect human nutrition, metabolism,
physiology, and immune development and function (Rinaldi et al.,
2018). It plays an important role in autoimmunity, and gut microbial
dysbiosis is known to be correlated with pathogenesis of MS (Chen,
et al., 2016). Importantly, speciﬁc microbiome signatures can be con-
sidered as biomarkers to predict the clinical outcome or disease-mod-
ifying treatment eﬃciency in MS (Calvo-Barreiro, Eixarch, Montalban,
& Espejo, 2017). Since some species of bacteria may worsen or improve
MS the gut microbiota of MS patients may be modiﬁed based on ther-
apeutic beneﬁt (Ezendam & van Loveren, 2008; van den Hoogen,
Laman, & t Hart, 2017). It can be reached by using probiotics, pre-
biotics, or synbiotics. Probiotics, as nonpathogenic microorganisms, are
able to interact with the gut microbiota and provide health beneﬁts
(Rinaldi et al., 2018) so that probiotic bacteria with immunoregulatory
properties are potentially considered to become a new therapeutic
treatment for autoimmune diseases (Atarashi et al., 2013). Diﬀerent
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species of Lactobacilli and Biﬁdobacteria has been a favorite of re-
searchers to study their eﬀects on CNS dysfunction in neurological
disorders (Akbari et al., 2016; Tamtaji et al., 2017).
Our previous study on patients with MS demonstrated that a mul-
tispecies probiotic supplement positively aﬀected some antioxidants
and metabolic biomarkers as well as mental health parameters
(Kouchaki et al., 2016). In the present work we aimed to assess if
support of the gut microbiota by a probiotic formulation consisting
diﬀerent species of Lactobacilli and Biﬁdobacteria including Biﬁdo-
bacterium infantis, Biﬁdobacterium lactis, Lactobacillus reuteri, Lactoba-
cillus casei, Lactobacillus plantarum and Lactobacillus fermentum (each
2× 109 CFU/d) inﬂuences clinical symptom, mental health, bio-
markers of inﬂammation and oxidative stress in patients with MS.
2. Material and methods
2.1. Trial design
Our study was performed from September 2017 through January
2018. This intervention was designed as a 16-week randomized,
double-blind, placebo-controlled trial.
2.2. Participants
The inclusion criteria were people with ages between 20 and 60,
course of disease relapsing–remitting MS (RRMS), identiﬁed according
to McDonald criteria and an expanded disability status scale (EDSS)
score≤4.5 referred to the Neurology Clinic of Shahid Beheshti Hospital
in Kashan city, Iran. The exclusion criteria were primary progressive MS
(PPMS), secondary progressive MS (SPMS), clinical relapse and gluco-
corticoid therapy during the past one month, pregnancy, women who
were lactating within the prior six month, patients with bearing ne-
phrolithiasis within the prior ﬁve years and consumers of probiotic or
synbiotic during the past three month. With the permission of patients
their documents were evaluated in our neurology clinic and the basic
and clinical data were recorded.
2.3. Ethics statements
This clinical evaluation was performed according to the Declaration
of Helsinki. Informed consent and signature were received from all
subjects before starting the intervention. The ethical committee of
Kashan University of Medical Sciences (KUMS) approved the research
proposal. In addition, the proposal is registered in the Iranian website
for registration of clinical trials (http://www.irct.ir:
IRCT2017082234497N2).
2.4. Study design
At ﬁrst, all patients were matched for disease severity based on
relapses, EDSS, type of medications, gender, age and BMI. Participants
were then randomly divided into two groups including the group re-
ceiving probiotic (n=24) and the group receiving placebo (n=24) for
16 weeks. Participants were asked not to alter their routine physical
activity or usual dietary intakes during the study and were asked not to
consume any supplements other than those provided to them by the
investigators.
We recorded for three-day food and physical activities at beginning
of study, after the third, sixth and ninth weeks of the intervention and,
end of the study.
2.5. Sample size
To calculate sample size, we used the standard formula suggested
for clinical trials by considering type one error (α) of 0.05 and type two
error (β) of 0.20 (power=80%). Based on a previous study (Kouchaki
et al., 2016), we used 0.60 as SD and 0.54 as the diﬀerence in mean (d)
of EDSS as key variable. Based on this, we needed 20 persons in each
group. Assuming 4 dropouts in each group, the ﬁnal sample size was
determined to be 24 persons per group.
2.6. Randomization
Randomization and blinding was performed before the allocation of
patients in the testing groups. This work was performed using com-
puter-generated random numbers that was hidden from the patients
and researchers until the end of the analysis.
2.7. Intervention
In the probiotic group, patients received probiotic capsules (pro-
duced by Zist Takhmir Company, Tehran, Iran) containing
Biﬁdobacterium infantis, Biﬁdobacterium lactis, Lactobacillus reuteri,
Lactobacillus casei, Lactobacillus plantarum and Lactobacillus fermentum
(each 2× 109 CFU/d). Multistrains and multispecies probiotics usually
demonstrate enhanced beneﬁcial eﬀects, which could be related to a
higher colonization rate, the synergistic combination of strain-speciﬁc
properties or even a symbiotic eﬀect between several microorganisms
(Gilgun-Sherki et al., 2004).
The patients in the placebo group received capsules containing
maltodextrine, the carrier of the probiotic bacteria. The probiotic and
placebo capsules were resembled in color, shape, size, packaging, smell
and taste. The treatment was lasted for 16 weeks.
2.8. Treatment adherence
The patients of both groups received placebo/probiotic capsules.
The participants were requested to consume the placebo/probiotic
capsule after dinner. The patients were asked to regress unused capsules
at each visit. The returned capsules were counted to determine number
of the capsules consumed.
2.9. Anthropometric measurements
Using a standard scale, weight and height of the patients were
measured in an overnight fasting condition in the beginning and end of
study. We calculated BMI of the patients as:
Weight (kg)/height(m )2
2.10. Assessment of outcomes
The primary outcomes were EDSS and inﬂammatory factors. The
secondary outcomes were mental health parameters, insulin resistance
and oxidative stress factors.
2.11. Clinical assessment
In the beginning and end of the study EDSS, relapses rate, disease
duration and medications were evaluated objectively by a neurologist.
2.12. Assessment of mental health
Mental health was evaluated using beck depression inventory (BDI),
general health questionnaire-28 (GHQ-28) and depression anxiety and
stress scale (DASS) at the baseline and end of study (Beck, Ward,
Mendelsohn, Mock, & Erbaugh, 1961; Crawford & Henry, 2004;
Goldberg & Hillier, 1979).
2.13. Blood samples collection
Fasting blood samples were obtained at the beginning and end of
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study in the early morning. The blood samples centrifuged at 1465g for
10min at room temperature and the serum and plasma were stored at
−80 °C. Then, biochemical tests were performed as soon as possible
after sample preparation.
2.14. Assessment of inﬂammatory factors
For measurement of serum high-sensitivity C-reactive protein (hs-
CRP) we used an ELISA kit (LDN, Nordhorn, Germany). The Giess
method was used for determination of plasma nitric oxide (NO) (Tatsch
et al., 2011). Other inﬂammatory and anti-inﬂammatory factors in-
cluding tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and
interleukin-10 (IL-10) concentrations were determined by ELISA kits
(sigma-aldrich, USA).
2.15. Assessment of oxidative stress biomarkers
Malondialdehyde (MDA), glutathione (GSH) and total antioxidant
capacity (TAC) of plasma were measured by the thiobarbituric acid
reactive substance method (Janero, 1990), the method of Beutler and
Gelbart (1985) and ferric reducing antioxidant power method (Benzie &
Strain, 1996), respectively. Also, other oxidative stress biomarkers in-
cluding 8-hydroxy-2′-deoxyguanosine (8-OHdG) and superoxide dis-
mutase (SOD) were evaluated by ELISA kits (MyBioSource).
2.16. Assessment of insulin resistance
Fasting plasma glucose (FPG) was measured by enzymatic kits (Pars
Azmun, Tehran, Iran). Homeostasis model of assessment-estimated in-
sulin resistance (HOMA-IR), homeostatic model assessment for B-cell
function (HOMA-B) and the quantitative insulin sensitivity check index
(QUICKI) were calculated based on suggested formulas. To measure
serum insulin we used a Monobind kit (California, USA) (Pisprasert,
Ingram, Lopez-Davila, Munoz, & Garvey, 2013).
2.17. Statistical methods
For evaluating whether the variables are normally distributed,
Kolmogrov-Smirnov test was applied to the data. Unpaired student t-
test was used to detect diﬀerences in anthropometric measures, EDSS,
parameters of mental health and metabolic indicators between the two
groups. To compare categorical variables, we used Pearson Chi-square
test. Adjustment for changes in baseline values of biochemical vari-
ables, age and BMI at baseline was performed by analysis of covariance
(ANCOVA). The P-value of< 0.05 was considered statistically sig-
niﬁcant. All statistical analyses used SPSS version 18.
3. Results
All participants in the placebo and probiotic groups were completed
the study (n= 24 for each group) (Fig. 1). The rate of compliance in the
present study was high, such that more than 90% of the prescribed
capsules were consumed in both groups. There was no side eﬀect after
probiotic consumption in the patients.
The basic and clinical characteristics of the patients are summarized
in Table 1. The t-test analysis showed that mean disease duration
(4.2 ± 0.42 vs. 5.2 ± 0.76, years; P= 0.26), age (34.79 ± 1.06 vs.
36.54 ± 1.44, years; P= 0.33), height (168.4 ± 1.68 vs.
166.7 ± 1.84, cm; P=0.49), weight (−0.2 ± 0.4 vs. −0.8 ± 0.17,
kg; P= 0.17) and BMI change (−0.1 ± 0.15 vs.−0.3 ± 0.05, kg/m2;
P=0.2) at the baseline and end of study were not statistically diﬀerent
in the probiotic compared to placebo group (Table 1). We found no
signiﬁcant change in the mean dietary macro- and micro-nutrient in-
takes between the two groups throughout the trial (Data not shown).
The t-test analysis showed that the probiotic treatment led to a
signiﬁcant decrease in EDSS score (−0.52 ± 0.04 vs.+ 0.16 ± 0.07,
P < 0.001) compared to the placebo group (Table 2). The probiotic
supplement also signiﬁcantly decreased mental health scores including
BDI (−5.08 ± 0.71 vs. −2.62 ± 0.78, P= 0.026), GHQ
(−6.7 ± 1.17 vs. −3.04 ± 1.13, P= 0.03) and DASS
(−12.54 ± 1.81 vs. −3.33 ± 2.26, P= 0.003). A pronounced de-
crease was observed in the plasma concentration of MDA
(−0.31 ± 0.75 vs. +0.15 ± 0.79, µmol/L; P < 0.001), 8-OHdG
(−6.72 ± 2.03 vs. +3.15 ± 1.57, ng/mL P < 0.001) in the probiotic
compared to placebo group. Additionally, the intervention resulted in a
signiﬁcant reduction in plasma levels of IL-6 (−0.2 ± 0.1 vs.
0.07 ± 0.08, pg/ml; P=0.01) and hs-CRP (−0.61 ± 0.58 vs.
+1.07 ± 0.5, µg/mL; P= 0.03), and a signiﬁcant increase in IL-10
(+0.46 ± 0.16 vs. −0.3 ± 0.22, pg/ml; P < 0.001) and NO
(+2.87 ± 1.16 vs. −1.64 ± 1.27, μmol/L; P=0.012). A trend to-
ward a greater decrease in serum insulin (−3.58 ± 0.55 vs.
−1.35 ± 0.89, μIU/mL; P= 0.04) and HOMA-IR (−1 ± 0.15 vs.
−0.33 ± 0.23, P=0.02) was observed in the probiotic group com-
pared with its placebo counterpart. The intervention not considerably
inﬂuenced the other biochemical proﬁles including SOD, GSH, TAC,
TNF-α, FPG and QUICKI (Table 2).
Adjustment for changes in the baseline values of biochemical vari-
ables, age and BMI at baseline was performed by ANCOVA. Our ﬁnding
showed that BDI, GHQ, SOD and TAC are altered after this adjustment.
So that, BDI and GHQ were signiﬁcant in the probiotic group compared
to the placebo one. After adjustment there was no signiﬁcant diﬀerence
in BDI (P= 0.05) and GHQ (P= 0.13) between the two groups. On the
other hand, while the serum level of SOD and TAC was not signiﬁcant
between the two groups they showed a post-adjustment signiﬁcant
diﬀerence (SOD, P=0.02; TAC, P= 0.04) (Table 3).
4. Discussion
This study evaluated the eﬀects of a probiotic supplementation on
disease severity, mental health, insulin resistance, inﬂammation and
oxidative stress in patients with MS. We found that four months bac-
teriotherapy had favorable eﬀects on EDSS, DASS, MDA, 8-OHdG, SOD,
TAC, IL-6, IL-10, NO, hs-CRP, insulin and HOMA-IR. However, the in-
tervention not suﬃciently aﬀected the other biochemical parameters.
Dietary factors and lifestyle may exacerbate or ameliorate MS
symptoms by modulating the inﬂammatory statuses in relapsing-re-
mitting MS and in primary-progressive MS (Von Geldern & Mowry,
2012). This is achieved by regulating both the metabolic and in-
ﬂammatory pathways in the human cell and the composition of gut
microbiota (Riccio et al., 2016). It is reported that the gut microbiota
importantly aﬀect the balance between inﬂammatory and anti-in-
ﬂammatory factor in immune responses in MS (Lee, Menezes, Umesaki,
& Mazmanian, 2011) and play an key role in depression (Lv et al.,
2017). This proposes was proved by our ﬁnding where consumption of
the probiotic supplementation resulted in a decreased EDSS, anxiety
and depression scores. Ait-Belgnaoui et al. reported that administration
of probiotics suppressed overactivity of hypothalamic-pituitaryadrenal
(HPA) axis due to psychological stress in rats (Ait-Belgnaoui et al.,
2014). Bercik et al. demonstrated that, by inﬂuencing activity of enteric
neurons, probiotics have beneﬁcial eﬀects on gut chronic inﬂammation-
induced anxiety (Bercik et al., 2011). In the previous study we de-
monstrated that administration of a probiotic formula for 12 weeks in
MS subjects leads to decreased EDSS, anxiety and depression scores
(Kouchaki et al., 2016).
We showed that the probiotic supplement decreased the levels of hs-
CRP and IL-6, and increased concentration of NO and IL-10.
Improvement of clinical scores by probiotic bacteria is contributed to
alteration of immune responses by inhibition of inﬂammatory cytokine
and increased anti-inﬂammatory cytokine and T regulatory
(Abdurasulova et al., 2016; Salehipour et al., 2017). Oral treatment
with the probiotic VSL#3 was associated with the induction of anti-
inﬂammatory peripheral immune responses and that interruption of the
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patriotic treatment was associated with a decrease in IL-10-producing
Treg cells (Tankou et al., 2018). In another study administration of
Lactobacillus strains prevented and delayed the clinical signs in the EAE
model of MS. In this study the probiotic supplement led to decreased
levels of the pro-inﬂammatory cytokines (TNF-α, IFN-γ and IL-17) and
increased levels of the anti-inﬂammatory cytokine IL-10 (Lavasani
et al., 2010). Secher et al. found that probiotic administration decreased
IL-6, increased IL-10 and improved clinical symptoms in an animal
model of MS (Secher et al., 2017). Tankou et al. reported that admin-
istration of a probiotic supplement decreased frequencies of Th1 and
Th17 in both healthy subjects and patients with MS (Tankou et al.,
2018). Probiotics may improve MS associated symptoms through de-
creasing IL-6 and preventing inﬁltration of harmful T cells such as Th17
cells into the CNS (Yamashita et al., 2017).
We proved that taking the supplement led to signiﬁcant reduction in
insulin, insulin resistance, MDA and 8-OHdG levels, and increased SOD,
TAC levels but did not aﬀect plasma levels of GSH. In a study was
shown that administration of probiotic for 12 weeks led to decreased
MDA and HOMA-IR and increased GSH (Tamtaji et al., 2018). In ad-
dition, the signiﬁcantly decreased HOMA-IR was seen among patients
with non-alcoholic fatty liver disease after administration probiotic
supplement for 12 weeks (Behrouz, Jazayeri, Aryaeian, Zahedi, &
Hosseini, 2017). It has been reported that clinical symptoms and EDSS
are correlated with increased oxidative stress and insulin resistance
(Kouchaki et al., 2017; Morel et al., 2017; Oliveira et al., 2014). It is
reported that 8-OHdG increased in patients with MS and that the
change is correlated with clinical severity of disease and demyelinated
brain lesion volume (Ljubisavljevic, Stojanovic, Basic, & Pavlovic,
2016). Suppressive eﬀect of probiotic supplementations on some oxi-
dative stressors in neurodegenerative disorders in clinical (Kouchaki
et al., 2016) and experimental (Athari Nik Azm et al., 2018; Davari,
Talaei, & Alaei, 2013) assessment has been conﬁrmed.
Mechanistically, oxidative stress, NO and insulin resistance aﬀects
High-mobility group box 1 protein (HMGB1) releasing in inﬂammatory
disease (Guzmán-Ruiz et al., 2014; Jiang & Pisetsky, 2006; Yu, Tang, &
Kang, 2015). In turn, HMGB1 changes Treg/Th17 balance to Th17
through the up-regulation of TLR4-IL-6 pathway (Li et al., 2014). On
the other hand, Lactobacillus reuteri and Lactobacillus casei induce reg-
ulatory T cells–produced IL-10 (Smits et al., 2005) which IL-10 sup-
presses IL-6 through the inhibition of nuclear factor-kappaB (NF-
kappaB) activation (Heyen, Ye, Finck, & Johnson, 2000).
Taken together, it seems, through modulation of gut microbiota, the
probiotic treatment may improve clinical symptoms by a balance in
inﬂammatory and anti-inﬂammatory responses in MS patients. Further,
decreased oxidative stressors might be involved in controlling the
clinical symptoms in the patients with MS and EDSS (Carlson & Rose,
Randomized (n=48)
Allocated to placebo (n=24)
All patients ended the
trial 
Analyzed (n=24)
Allocated to probiotic (n=24)
All patients ended the
trial 
Analyzed (n=24)
Assessed for eligibility (n=65)
Excluded:






















Fig. 1. Summary of patient ﬂow.
Table 1






Number of subjects 24 24 –
Gender (%) Male 6 (25) 6 (25) > 0.99b
Female 18 (75) 18 (75)
Age (y) 36.54 ± 1.44 34.79 ± 1.06 0.33a
Disease duration (y) 5.2 ± 0.76 4.2 ± 0.42 0.26a
Height (cm) 166.7 ± 1.84 168.4 ± 1.68 0.49a
Weight (kg) Study
baseline
68.1 ± 1.94 70.16 ± 1.85 0.44a
End of
trial
67.2 ± 1.89 69.8 ± 1.82 0.31a





24.5 ± 0.63 24.7 ± 0.55 0.81a
End of
trial
24.2 ± 0.62 24.6 ± 0.53 0.61a




Avonex 20 (83.3) 20 (83.3) > 0.99b
Rebif 4 (16.7) 4 (16.7)
Data are presented as means ± SEM.
MS, multiple sclerosis; BMI, Body mass index.
a Obtained from independent t test.
b Obtained from Pearson Chi-square test.
M. Salami et al. Journal of Functional Foods 52 (2019) 8–13
11
2006; Gilgun-Sherki, Melamed, & Oﬀen, 2004). Emerging evidence
highlights that the gut microbiota modiﬁcation open a new window for
treatment of the autoimmune disease MS (Secher et al., 2017; Tankou
et al., 2018). However, more preclinical and clinical studies are
required to signature the therapeutic potentials of probiotic bacteria in
the treatment of patients with MS. The limitation of the study was
diﬃculty in counting microbial ﬂora in the MS patients. Future pro-
spects in MS research should regard eﬀects of probiotic supplement on
gut microbiota composition, NF-kB, HMGB1 and T and B cells in pa-
tients with MS.
5. Conclusion
Overall, the administration of probiotic bacteria may inﬂuence the
motor and mental behaviors by modulation of inﬂammatory and oxi-
dative biomarkers in patients with MS. The probiotic supplements could
be a new strategy for improving and controlling MS severity.
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meters in patients with multiple sclerosis that received either probiotic or
placebo.
Placebo group (n=24) Probiotic group (n= 24) Pa
EDSS 0.15 ± 0.05 −0.51 ± 0.05 < 0.001
SOD (U/mL) 12.22 ± 4.03 0.92 ± 4.03 0.02
8-OHdG (ng/
mL)
0.78 ± 1.66 −4.35 ± 1.66 0.04
MDA (µmol/L) 0.11 ± 0.5 −0.27 ± 0.5 < 0.001
GSH (µmol/L) 12.05 ± 12.39 35.96 ± 12.39 0.18
TAC (mmol/L) −17.46 ± 7.15 4.03 ± 7.15 0.04
IL-6 (pg/ml) 0.91 ± 0.09 −0.21 ± 0.09 0.03
IL-10 (pg/ml) −0.41 ± 0.16 0.56 ± 0.16 < 0.001
TNF-α (pg/ml) 0.12 ± 0.22 −0.09 ± 0.22 0.51
hs-CRP (µg/mL) 0.98 ± 0.42 −0.52 ± 0.42 0.01
NO (μmol/L) −1.52 ± 0.83 2.75 ± 0.83 0.001
Insulin (μIU/
mL)
−1.34 ± 0.76 −3.59 ± 0.76 0.04
HOMA-IR −0.33 ± 0.2 −0.99 ± 0.2 0.02
QUICKI 0.017 ± 0.006 0.032 ± 0.006 0.9
GHQ −3.57 ± 1.17 −6.17 ± 1.17 0.13
DASS −3.44 ± 2.05 −12.43 ± 2.05 0.004
BDI −3.06 ± 0.54 −4.64 ± 0.54 0.05
All values are means ± SEM.
BDI, Beck depression inventory; DASS, Depression anxiety and stress scale;
EDSS, Expanded disability status scale; FPG, Fasting plasma glucose; GHQ,
General health questionnaire; GSH, Total glutathione; HOMA-IR, Homeostasis
model of assessment-estimated insulin resistance; hs-CRP, High-sensitivity C-
reactive protein; IL-6, Interleukins-6; IL-10, Interleukins-10; MDA,
Malondialdehyde; NO, Nitric oxide; QUICKI, Quantitative insulin sensitivity
check index; SOD, Superoxide dismutase; TAC, Total antioxidant capacity; TNF-
α, Tumor necrosis factor-α; 8-OHdG, 8-hydroxy-2′ -deoxyguanosine.
a Obtained from analysis of ANCOVA adjusted for baseline values+ age and
baseline BMI.
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